Scholarlink

<p>The increasing prevalence of carbapenem-resistant <i>Klebsiella pneumoniae</i> (CRKP) constitutes a substantial hazard to human health. Phage therapy represents a promising alternative for treating CRKP infections. This research isolated a novel phage, vB_LSKP32, which targets the KL64 capsular type of CRKP from hospital sewage samples. The phage vB_LSKP32 adsorbs rapidly to host cells, features a 5–10&#xa0;min latent period, and yields approximately 56 ± 3 new phage particles per infected cell. It remains stable and infectious under conditions ranging from 4&#xa0;°C to 50&#xa0;°C and pH 4 to 11. The phage vB_LSKP32 genome contains a 40,942&#xa0;bp linear dsDNA with a GC content of 52.92%. Genome annotation predicted 50 ORFs, with no evidence of antibiotic resistance genes, virulence genes, lysogeny-related genes and tRNA. Through intergenomic similarity studies and phylogenetic analyses, vB_LSKP32 was classified as a novel species within the genus <i>Przondovirus</i>, family <i>Autographiviridae</i>. Phage vB_LSKP32 exhibited efficient suppression of host bacterial proliferation for approximately 7&#xa0;h in vitro. Moreover, it significantly enhanced the survival rate of <i>Galleria mellonella</i> larvae post-infection, with the survival rate positively correlating with phage titer. Notably, larvae treated at an MOI of 100 elevated the survival rate to 90% (vs. 15% in controls). Our findings suggest that phage vB_LSKP32 shows significant potential as an antimicrobial agent against KL64-type CRKP.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Isolation, characterization, and therapeutic assessment of novel phage vB_LSKP32 targeting KL64-type carbapenem-resistant Klebsiella pneumoniae

  • 期刊论文

  • 发表日期：

    2026年2月19日

查看全文
  • Junjie Lan,
  • Weiping Wu,
  • Liupin Du,
  • Qi Liu

摘要

The increasing prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) constitutes a substantial hazard to human health. Phage therapy represents a promising alternative for treating CRKP infections. This research isolated a novel phage, vB_LSKP32, which targets the KL64 capsular type of CRKP from hospital sewage samples. The phage vB_LSKP32 adsorbs rapidly to host cells, features a 5–10 min latent period, and yields approximately 56 ± 3 new phage particles per infected cell. It remains stable and infectious under conditions ranging from 4 °C to 50 °C and pH 4 to 11. The phage vB_LSKP32 genome contains a 40,942 bp linear dsDNA with a GC content of 52.92%. Genome annotation predicted 50 ORFs, with no evidence of antibiotic resistance genes, virulence genes, lysogeny-related genes and tRNA. Through intergenomic similarity studies and phylogenetic analyses, vB_LSKP32 was classified as a novel species within the genus Przondovirus, family Autographiviridae. Phage vB_LSKP32 exhibited efficient suppression of host bacterial proliferation for approximately 7 h in vitro. Moreover, it significantly enhanced the survival rate of Galleria mellonella larvae post-infection, with the survival rate positively correlating with phage titer. Notably, larvae treated at an MOI of 100 elevated the survival rate to 90% (vs. 15% in controls). Our findings suggest that phage vB_LSKP32 shows significant potential as an antimicrobial agent against KL64-type CRKP.